• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Kinin receptor subtypes.

作者信息

Regoli D, Rhaleb N E, Drapeau G, Dion S

机构信息

Department of Pharmacology, Medical School, University of Sherbrooke, Canada.

出版信息

J Cardiovasc Pharmacol. 1990;15 Suppl 6:S30-8.

PMID:1697358
Abstract

Bradykinin, kallidin, and some of their metabolites exert potent biological effects in a variety of organs and tissues. These effects are mediated by specific receptors, of two different types B1 and B2, according to the classification proposed in 1980 by Regoli and Barabé. This classification has recently been challenged by several authors on the basis of data obtained with a variety of synthetic analogs (both agonists and antagonists) of bradykinin and kallidin. B2-receptor subtypes and even a new receptor type, B3 have been considered. Other workers have shown that some of the kinins' biological effects, such as the activation of prostaglandins or histamine release, may occur through nonreceptor mechanisms. Recently, a variety of new kinin-related peptides have been prepared and tested. In particular, new selective agonists for both B1 and B2 receptors have been identified and used for receptor characterization, particularly in complex biological systems. Antagonists are critically reviewed, because several of them are in effect partial agonists. Pure antagonists have been obtained and used for receptor characterization in various organs. Activation of receptors and nonreceptor mechanisms by kinins bring about direct effects on smooth muscles and other cells and indirect effects mediated by endothelium-derived relaxing factor, or by prostacyclin, prostaglandins, leukotrienes, histamine, etc. Interaction of kinins with their receptors activates second messengers that may be different from one cell to another (in the same tissue) and that are activated either by kinins or by other endogenous mediators released by kinins.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

相似文献

1
Kinin receptor subtypes.
J Cardiovasc Pharmacol. 1990;15 Suppl 6:S30-8.
2
Receptors for bradykinin and related kinins: a critical analysis.缓激肽及相关激肽的受体:批判性分析
Can J Physiol Pharmacol. 1993 Aug;71(8):556-67. doi: 10.1139/y93-079.
3
[Kinin B1 and B2 receptor antagonists and therapeutic perspectives].
Therapie. 1995 Jan-Feb;50(1):9-18.
4
Involvement of the kinin-forming system in the physiopathology of rheumatoid inflammation.激肽生成系统在类风湿性炎症生理病理学中的作用。
Agents Actions Suppl. 1992;38 ( Pt 3):343-61.
5
Bradykinin stimulates the production of cyclic GMP via activation of B2 kinin receptors in cultured porcine aortic endothelial cells.缓激肽通过激活培养的猪主动脉内皮细胞中的B2激肽受体来刺激环鸟苷酸的产生。
J Pharmacol Exp Ther. 1990 Feb;252(2):581-5.
6
B1 and B2 kinin receptors on cultured rabbit superior mesenteric artery smooth muscle cells: receptor-specific stimulation of inositol phosphate formation and arachidonic acid release by des-Arg9-bradykinin and bradykinin.培养的兔肠系膜上动脉平滑肌细胞上的B1和B2激肽受体:去精氨酸9-缓激肽和缓激肽对肌醇磷酸形成和花生四烯酸释放的受体特异性刺激
J Pharmacol Exp Ther. 1993 Feb;264(2):930-7.
7
New selective bradykinin receptor antagonists and bradykinin B2 receptor characterization.
Trends Pharmacol Sci. 1990 Apr;11(4):156-61. doi: 10.1016/0165-6147(90)90067-I.
8
Classification of kinin receptors.激肽受体的分类。
Biol Chem. 2001 Jan;382(1):31-5. doi: 10.1515/BC.2001.005.
9
Mechanisms regulating the expression, self-maintenance, and signaling-function of the bradykinin B2 and B1 receptors.调节缓激肽B2和B1受体的表达、自我维持及信号功能的机制。
J Cell Physiol. 2002 Dec;193(3):275-86. doi: 10.1002/jcp.10175.
10
Converting enzyme inhibitors and the interaction between kinins and eicosanoids.转化酶抑制剂以及激肽与类花生酸之间的相互作用。
J Cardiovasc Pharmacol. 1990;15 Suppl 6:S60-8.

引用本文的文献

1
A comprehensive review on current understanding of bradykinin in COVID-19 and inflammatory diseases.关于缓激肽在 COVID-19 和炎症性疾病中的最新认识的全面综述。
Mol Biol Rep. 2022 Oct;49(10):9915-9927. doi: 10.1007/s11033-022-07539-2. Epub 2022 May 21.
2
Tissue Kallikrein Exacerbating Sepsis-Induced Endothelial Hyperpermeability is Highly Predictive of Severity and Mortality in Sepsis.组织激肽释放酶加剧脓毒症诱导的内皮细胞高通透性,对脓毒症的严重程度和死亡率具有高度预测性。
J Inflamm Res. 2021 Jul 15;14:3321-3333. doi: 10.2147/JIR.S317874. eCollection 2021.
3
Evidence and evidence gaps of medical treatment of non-tumorous diseases of the head and neck.
头颈部非肿瘤性疾病的医学治疗证据及证据空白
GMS Curr Top Otorhinolaryngol Head Neck Surg. 2016 Dec 15;15:Doc02. doi: 10.3205/cto000129. eCollection 2016.
4
Kallikrein-kinin in stem cell therapy.干细胞治疗中的激肽释放酶-激肽系统
World J Stem Cells. 2014 Sep 26;6(4):448-57. doi: 10.4252/wjsc.v6.i4.448.
5
The kallikrein-kinin system as a regulator of cardiovascular and renal function.激肽释放酶-激肽系统作为心血管和肾功能的调节剂。
Compr Physiol. 2011 Apr;1(2):971-93. doi: 10.1002/cphy.c100053.
6
Angiotensin-converting enzyme and bradykinin gene polymorphisms and cough: A meta-analysis.血管紧张素转换酶和缓激肽基因多态性与咳嗽:一项荟萃分析。
World J Cardiol. 2011 Oct 26;3(10):329-36. doi: 10.4330/wjc.v3.i10.329.
7
The lupus-susceptibility gene kallikrein downmodulates antibody-mediated glomerulonephritis.狼疮易感基因激肽释放酶可下调抗体介导的肾小球肾炎。
Genes Immun. 2009 Jul;10(5):503-8. doi: 10.1038/gene.2009.7. Epub 2009 Mar 5.
8
Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation.组织激肽释放酶通过直接激活激肽B2受体发挥心脏保护作用,而不依赖于激肽的形成。
Hypertension. 2008 Oct;52(4):715-20. doi: 10.1161/HYPERTENSIONAHA.108.114587. Epub 2008 Sep 2.
9
Tissue kallikrein promotes neovascularization and improves cardiac function by the Akt-glycogen synthase kinase-3beta pathway.组织激肽释放酶通过Akt-糖原合成酶激酶-3β途径促进新生血管形成并改善心脏功能。
Cardiovasc Res. 2008 Dec 1;80(3):354-64. doi: 10.1093/cvr/cvn223. Epub 2008 Aug 9.
10
Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3beta activation.组织激肽释放酶通过激活缓激肽B2受体和糖原合酶激酶-3β来预防压力超负荷诱导的心脏肥大。
Cardiovasc Res. 2007 Jan 1;73(1):130-42. doi: 10.1016/j.cardiores.2006.10.014. Epub 2006 Oct 27.